Genscript Biotech Future Growth
Future criteria checks 5/6
Genscript Biotech is forecast to grow earnings and revenue by 112.7% and 39.9% per annum respectively. EPS is expected to grow by 112.5% per annum. Return on equity is forecast to be 9.5% in 3 years.
Key information
112.7%
Earnings growth rate
112.5%
EPS growth rate
| Life Sciences earnings growth | 26.2% |
| Revenue growth rate | 39.9% |
| Future return on equity | 9.5% |
| Analyst coverage | Good |
| Last updated | 23 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,680 | 255 | -49 | 778 | 11 |
| 12/31/2025 | 1,809 | 42 | -200 | 97 | 12 |
| 12/31/2024 | 1,200 | -170 | -330 | -99 | 12 |
| 6/30/2024 | 1,010 | -177 | -276 | -20 | N/A |
| 3/31/2024 | 925 | -136 | -410 | -153 | N/A |
| 12/31/2023 | 840 | -95 | -543 | -287 | N/A |
| 9/30/2023 | 773 | -140 | -506 | -266 | N/A |
| 6/30/2023 | 707 | -185 | -523 | -245 | N/A |
| 3/31/2023 | 667 | -206 | -431 | -183 | N/A |
| 12/31/2022 | 626 | -227 | -339 | -120 | N/A |
| 9/30/2022 | 598 | -315 | -321 | -142 | N/A |
| 6/30/2022 | 570 | -403 | -304 | -163 | N/A |
| 3/31/2022 | 530 | -381 | -289 | -150 | N/A |
| 12/31/2021 | 490 | -359 | -274 | -137 | N/A |
| 9/30/2021 | 483 | -265 | -265 | -127 | N/A |
| 6/30/2021 | 454 | -183 | -256 | -118 | N/A |
| 3/31/2021 | 422 | -194 | -268 | -134 | N/A |
| 12/31/2020 | 391 | -205 | -279 | -151 | N/A |
| 9/30/2020 | 354 | -194 | -171 | -48 | N/A |
| 6/30/2020 | 318 | -183 | -64 | 54 | N/A |
| 3/31/2020 | 296 | -140 | -103 | 12 | N/A |
| 12/31/2019 | 273 | -97 | -142 | -30 | N/A |
| 9/30/2019 | 257 | -59 | -207 | -116 | N/A |
| 6/30/2019 | 241 | -22 | -272 | -202 | N/A |
| 3/31/2019 | 236 | 0 | -18 | 53 | N/A |
| 12/31/2018 | 231 | 21 | 236 | 308 | N/A |
| 9/30/2018 | 216 | 24 | 266 | 338 | N/A |
| 6/30/2018 | 201 | 27 | 297 | 369 | N/A |
| 3/31/2018 | 177 | 26 | N/A | 195 | N/A |
| 12/31/2017 | 153 | 26 | N/A | 21 | N/A |
| 9/30/2017 | 139 | 27 | N/A | 24 | N/A |
| 6/30/2017 | 125 | 28 | N/A | 27 | N/A |
| 3/31/2017 | 120 | 27 | N/A | 30 | N/A |
| 12/31/2016 | 115 | 26 | N/A | 33 | N/A |
| 9/30/2016 | 107 | 26 | N/A | 29 | N/A |
| 6/30/2016 | 99 | 25 | N/A | 25 | N/A |
| 3/31/2016 | 93 | 21 | N/A | 22 | N/A |
| 12/31/2015 | 87 | 18 | N/A | 20 | N/A |
| 9/30/2015 | 82 | 13 | N/A | 18 | N/A |
| 6/30/2015 | 78 | 8 | N/A | 16 | N/A |
| 3/31/2015 | 74 | 7 | N/A | 14 | N/A |
| 12/31/2014 | 70 | 6 | N/A | 12 | N/A |
| 12/31/2013 | 60 | 6 | N/A | 12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: G51 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: G51 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: G51 is expected to become profitable in the next 3 years.
Revenue vs Market: G51's revenue (39.9% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: G51's revenue (39.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: G51's Return on Equity is forecast to be low in 3 years time (9.5%).